AmerisourceBergen Shares Perspectives on SCOTUS ACA Decision
At AmerisourceBergen, we are united in creating
healthier futures and believe in the accessibility and affordability of health
and pharmaceutical care. In alignment with that purpose, we’re pleased with
today’s Supreme Court Affordable Care Act decision which creates peace of mind
for patients everywhere as necessary protections will continue, including
essential bans on lifetime benefit caps and restrictions based on pre-existing
conditions. In addition, today’s decision effectively preserves the Biologics
Price Competition and Innovation Act of 2009 (BPCIA), which enables a critical
pathway for Biosimilar therapies to come to market. The preservation of the
BPCIA pathway is a win for patient access and pharmaceutical innovation.
Biosimilars play an essential role in lowering drug prices across therapeutic
categories and expanding patient access to treatments.